妊娠毒血症診斷市場規模、佔有率和成長分析（按檢測類型、產品、最終用戶和地區）- 產業預測 2025-2032

2023 年妊娠毒血症診斷市場規模價值 10.9 億美元，預計將從 2024 年的 11.2 億美元成長到 2032 年的 14.3 億美元，預測期內（2025-2032 年）的複合年成長率為 3.1%。

隨著人們對孕產婦健康意識的增強以及妊娠相關併發症的複雜性，全球妊娠毒血症診斷市場正在經歷顯著成長。妊娠毒血症是一種嚴重的高血壓疾病，對產科護理構成重大風險，對準確和早期診斷方法的需求日益增加。因此，主要市場相關人員正在創新診斷技術，旨在改善早期檢測和管理。醫療支出增加、新興市場醫療基礎設施加強、產科護理採用先進醫療技術等因素進一步推動了市場擴張。然而，挑戰包括先進診斷方法的成本高昂，以及某些地區獲得醫療服務的機會有限。隨著新型生物標記和非侵入性診斷方法研究的進步，市場在可預見的未來可能會繼續發展。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

妊娠毒血症診斷市場規模（按檢測類型和複合年成長率） (2025-2032)

• 市場概況
• 血液檢查
• 尿液檢查
• 其他

妊娠毒血症診斷市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 裝置
• 耗材

妊娠毒血症診斷市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院
• 專科門診
• 診斷中心
• 其他

妊娠毒血症診斷市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Diabetomics Inc.（United States）
• DRG Instruments GmbH（Germany）
• F. Hoffmann-La Roche Ltd（Switzerland）
• PerkinElmer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific（United States）
• GE Healthcare（United States）
• Abbott Laboratories（United States）
• Acon Laboratories, Inc.（United States）
• Arkray, Inc.（Japan）
• Bio-Rad Laboratories, Inc.（United States）
• Cardinal Health（United States）
• Danaher Corporation（Beckman Coulter, Inc.）（United States）
• DIRUI Industrial Co., Ltd.（China）
• Metabolomic Diagnostics Ltd.（Ireland）
• Sera Prognostics（United States）
• Synlab Group（Germany）
• Microlife Corporation（Switzerland）
• Bayer AG（Germany）
• Progenity Inc.（United States）

結論和建議

Preeclampsia Diagnostics Market size was valued at USD 1.09 billion in 2023 and is poised to grow from USD 1.12 billion in 2024 to USD 1.43 billion by 2032, growing at a CAGR of 3.1% during the forecast period (2025-2032).

The global preeclampsia diagnostics market is experiencing significant growth, driven by heightened awareness surrounding maternal health and the complexities of pregnancy-related complications. As preeclampsia, a serious hypertensive condition, poses substantial risks in obstetrics, the demand for precise and early diagnostic methods is escalating. Consequently, major market players are innovating diagnostic technologies aimed at improving early detection and management. Factors such as rising healthcare expenditures, enhancements in healthcare infrastructure in emerging markets, and the incorporation of advanced medical technologies in obstetric care are further propelling market expansion. However, high costs of sophisticated diagnostic methods and limited healthcare access in certain regions may pose challenges. With ongoing research into novel biomarkers and non-invasive diagnostics, the market is poised for continued advancements in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Preeclampsia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Preeclampsia Diagnostics Market Segments Analysis

Global Preeclampsia Diagnostics Market is segmented by Test Type, Product, End-user and region. Based on Test Type, the market is segmented into Blood Tests, Urine Analysis and Others. Based on Product, the market is segmented into Instruments and Consumables. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Preeclampsia Diagnostics Market

The Preeclampsia Diagnostics market is driven by the challenges associated with accurately diagnosing the condition in pregnant women. A solitary increase in blood pressure is not a definitive indicator of preeclampsia, complicating the diagnosis process. Furthermore, many expectant mothers lack awareness of preeclampsia and its associated risks, which can lead to hypertension during pregnancy going undetected until it escalates, thereby restricting timely intervention opportunities. This gap in knowledge not only poses significant health risks to the women affected but also heightens the likelihood of increased infant mortality rates, underscoring the urgent need for effective diagnostic solutions and education.

Restraints in the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market faces significant challenges due to the complexities involved in diagnosing the condition in pregnant women. A mere increase in blood pressure is not a definitive indicator of preeclampsia, making accurate identification difficult. Furthermore, a considerable number of expectant mothers lack knowledge about preeclampsia, which severely limits their understanding of the associated risks. As hypertension often goes undetected until more severe symptoms arise, this oversight restricts timely intervention options. The resultant unawareness poses considerable risks to maternal health and significantly heightens infant mortality rates, emphasizing the critical need for improved awareness and diagnostic methods in this area.

Market Trends of the Preeclampsia Diagnostics Market

The global preeclampsia diagnostics market is witnessing a significant trend towards early risk assessment for pregnant women, propelling the adoption of biomarker-based tests designed for the early detection of this condition. By focusing on specific biological markers, healthcare providers can more accurately identify potential preeclampsia cases, which enables timely interventions crucial for improving maternal and fetal health outcomes. This proactive diagnostic approach aligns with the overarching goals of healthcare systems to enhance maternal care and reduce the adverse effects of preeclampsia on pregnancies. As awareness and demand for early intervention grow, the market for innovative diagnostic solutions is expected to flourish in tandem.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Preeclampsia Diagnostics Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Blood Tests
• Urine Analysis
• Others

Global Preeclampsia Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
• Consumables

Global Preeclampsia Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

Global Preeclampsia Diagnostics Market Size & CAGR (2025-2032)

• North America (Test Type, Product, End-user)
  • US
  • Canada
• Europe (Test Type, Product, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Product, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Product, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Product, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Diabetomics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DRG Instruments GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkray, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DIRUI Industrial Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Diagnostics Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sera Prognostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlab Group (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microlife Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenity Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations